Added to YB: 2025-06-24
Pitch date: 2025-05-07
ABEO [bullish]
Abeona Therapeutics Inc.
+5.14%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Market Cap
$325.4M
Pitch Price
$5.25
Price Target
22.71 (+311%)
Dividend
N/A
EV/EBITDA
-2.04
P/E
6.25
EV/Sales
12.40
Sector
Biotechnology
Category
growth
Show full summary:
Abeona Therapeutics Inc. - $ABEO
ABEO: FDA-approved Zevaskyn for RDEB at $3.1M per treatment offers durable, one-time therapy for large wounds vs Vyjuvek's weekly application. 750 US patients + $150M PRV sale coming. Projecting $152.5M revenue 2026, $244M 2027, $120M EBIT. Trading at <3x 2026E EBIT, PT $22.71 (294% upside).
Read full article (4 min)